Premium
Preservation of heart function in diabetic rats by the combined effects of muscle cell implantation and insulin therapy
Author(s) -
Kim ByungOk,
Verma Subodh,
Weisel Richard D.,
Fazel Shafie,
Jia ZhiQiang,
Mizuno Tomohiro,
Li RenKe
Publication year - 2008
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2007.11.007
Subject(s) - medicine , insulin , diabetic cardiomyopathy , transplantation , cardiac function curve , diabetes mellitus , cardiomyopathy , heart failure , streptozotocin , cardiac muscle , endocrinology , myocyte , cardiology , heart transplantation
Background: Diabetic cardiomyopathy is a common cause of heart failure in diabetic patients, but current treatments do not directly improve ventricular function. Cell transplantation can prevent cardiac dilatation after injury, and may also prevent congestive heart failure in diabetic cardiomyopathy. Aim: This study evaluated the functional effects of smooth muscle cells (SMCs) implanted into the myocardium of insulin‐ and non insulin‐treated diabetic rats. Methods: Four weeks after streptozotocin infusion, adult Wistar rats were implanted with BrdU‐labelled SMCs or culture media ( N =12/group). Six rats in each group were also treated with insulin. Echocardiograms were performed at 0, 4 and 8 weeks after streptozotocin injection, and histology and heart function were evaluated at 4 weeks after implantation. Results: Blood glucose levels decreased after insulin treatment. Among cell‐injected rats, histology indicated that those that did not receive insulin retained fewer surviving BrdU+ SMCs, and a smaller volume of myocardial tissue positive for αsmooth muscle actin. Cardiac function was preserved in the insulin‐treated groups relative to those that did not receive insulin. Among insulin‐treated rats, the cell‐injected group functioned better than the media‐injected group. Conclusions: Diabetic cardiomyopathy is partially treatable with insulin; however, a combination of SMC transplantation and insulin treatment produced the best functional result. Cell transplantation may prevent the progression of diabetic cardiomyopathy in patients whose glucose levels are controlled with insulin.